… To overcome this problem, research into novel anti-tuberculosis targets and drug … the field
of anti-tuberculosis drug discovery. The predominant focus is on anti-tuberculosis agents that …

Over 480 000 cases of multidrug-resistant (MDR) tuberculosis (TB) occur every year globally,
9% of them being affected by extensively drug-resistant (XDR) strains of Mycobacterium …

… The classification of anti-tuberculosis (TB) drugs is important … -resistant (MDR) and extensively
drug-resistant (XDR) TB … anti-TB drugs based on current evidence on each drug. In the …

… The drugs in this category are isoniazid, rifampin, ethambutol, pyrazinamide and streptomycin.
Second-line anti-tuberculosis drugs … These drugs include para-aminosalicylic acid (PAS), …

… drugs with uncertain modes of action and the pyrrole SQ-109, a cell wall inhibitor. Anti-tuberculosis
drugs … it is unnecessary to match these when giving drug combinations. The effects of …

… for multidrug therapy, the emergence of drug resistance, HIV co-infection and persistent …
for new anti-tuberculosis drugs. Strategies to search for new anti-tuberculosis drugs involve: …

… -line drugs, are becoming more common.3, 4 These strains, termed extensively drug resistant
(… with a drive to introduce new anti-tuberculosis drugs, the situation is only set to worsen. …

… anti-tuberculosis drug resistance surveillance were developed.These guidelines introduced
standard definitions and the procedures to implement drug … -line anti-tuberculosis drugs, INH…

… Several efforts are underway to develop new drugs, within the … overview of the six drug
candidates currently in clinical … World Health Organization (WHO), Anti-tuberculosis drug …

… The long current drug regimen, the emergence of drug resistant strains and HIV co-infection …
for new anti-tuberculosis drugs. A number of new potential anti-tuberculosis drug candidates …